From: Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
 | Biomarkers | The predictive effect of biomarkers | Reference | ||
---|---|---|---|---|---|
Tumor feature | PD-L1 expression level | 15.4 months, 95%CI: 10.6–18.8 months (median OS) 53%, 95%CI: 30–75% (DCB) HR: 0.63, 95%CI: 0.47–0.86 (OS) | |||
TMB | tTMB 29 vs. 6% (ORR) HR: 0.62, 95%CI: 0.38–1.00 (PFS) HR: 0.58, 97.5%CI: 0.41–0.81 (PFS) bTMB HR: 0.39, 95%CI: 0.18–0.84 (PFS) | ||||
Neoantigens | HR: 0.23, 95%CI: 0.09–0.58 (median PFS) 92 vs. 11% (DCB) | ||||
Driver gene mutations | KRAS OR: 1.51; 95%CI: 1.17–1.96 (ORR) TP53 HR: 0.32, 95%CI: 0.16–0.63 (PFS) EGFR 5.3 months, 95%CI: 1.3–12.4 months (median PFS) ALK 0.6 months, 95% CI: 0.2–2.1 months (PFS) MET 17%, 95%CI: 6%-36% (ORR) NFE2L2/KEAP1 22.52 months vs. 12.89 months (median OS) | ||||
miRNA | HR: 0.45, 95%CI: 0.25–0.76 (median PFS) HR: 0.39, 95%CI: 0.15–0.68 (median OS) | [71] | |||
Tumor microenvironment | TIL | HR: 0.954, 95%CI: 0.965–0.983 (DFS) HR: 0.965, 95%CI: 0.931–1.001 (OS) | [78] | ||
Biomarkers in peripheral blood | CAMLs | HR: 2.5, 95%CI: 1.1–5.8 (PFS) HR: 3.5, 95%CI: 1.3–9.6 (OS) | [109] | ||
CTECs | 5 months, 95%CI: 3.9–6.1 months (median PFS) | [116] | |||
Other peripheral blood cells | NLR HR: 1.44, 95%CI: 1.26–1.65 (median PFS) HR: 2.86, 95%CI: 2.11–3.87 (median OS) | [119] | |||
Other | Gut microbiota | HR: 4.2, 95%CI: 1.42–12.3 (PFS) | [130] | ||
Patients clinical characteristics | Gender male: HR: 0.76, 95%CI: 0.64–0.91 female: HR: 0.44, 95%CI: 0.25–0.76 (OS) Smoking 36 vs. 26 vs. 14% (current smokers vs. former smokers vs. non-smokers) PIOS HR: 0.469, 95%CI: 0.295–0.747 (median PFS) HR: 0.539, 95%CI: 0.317–0.918 (median OS) |